Trial Profile
Real World Outcomes of Intravitreal Anti-vascular Endothelial Growth Factors for Neovascular Age-related Macular Degeneration in Taiwan -A 4-Year Longitudinal Studyneovascular Age-related Macular Degeneration in Taiwan -A 4-Year Longitudinal Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Nov 2017
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- Acronyms OIVAEGFFAMDIT
- 01 Nov 2017 New trial record